docetaxel
sanofi,aventis
['radio', 'docetaxel', 'head and neck']
results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation #asco22 #practicechanging 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis